New data confirms Enveric’s lead neuroplastogen acts on a serotonin receptor tied to depression, Parkinson’s, and migraine. Enveric Biosciences has announced that EB-003, its oral, non-hallucinogenic neuroplastogen, also acts as an agonist at the serotonin 5‑HT1B receptor. The new receptor binding data broadens the compound’s therapeutic reach to central nervous system (CNS) conditions such as depression, Parkinson’s disease, and migraine, reinforcing its candidacy as a prescription-ready neuroplastogenic agent.
